Type to search




We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.

Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.

We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.

Posts Featuring Novavax